{"id":"exenatide-infusion","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to improved glycemic control and weight reduction in patients with type 2 diabetes.","oneSentence":"Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce blood glucose in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:35.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (investigational infusion formulation)"}]},"trialDetails":[{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT04307797","phase":"PHASE4","title":"Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-01-18","conditions":"Type 2 Diabetes, Obesity","enrollment":10},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT03835013","phase":"NA","title":"Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2019-02-11","conditions":"Cardiovascular Diseases","enrollment":26},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT02432976","phase":"PHASE2, PHASE3","title":"Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-05","conditions":"Quality of Life","enrollment":64},{"nctId":"NCT02690987","phase":"EARLY_PHASE1","title":"Gut Hormones in Obesity, Nicotine and Alcohol Dependence","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2015-08","conditions":"Obesity, Smoking Cessation, Alcoholism","enrollment":95},{"nctId":"NCT02058940","phase":"PHASE4","title":"Intravenous Exenatide in Patients With Acute Brain Injury","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-08","conditions":"Brain Injuries","enrollment":8},{"nctId":"NCT01857895","phase":"PHASE1","title":"Feasibility Study of Exenatide by Continuous Subcutaneous Infusion","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-16","conditions":"Obesity","enrollment":10},{"nctId":"NCT01969149","phase":"PHASE2, PHASE3","title":"Exenatide for Stress Hyperglycemia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-01","conditions":"Stress Hyperglycemia","enrollment":110},{"nctId":"NCT02442791","phase":"NA","title":"GLP-1 Analogs for Neuroprotection After Cardiac Arrest","status":"COMPLETED","sponsor":"Jesper Kjaergaard","startDate":"2014-06","conditions":"Cardiac Arrest, Coma","enrollment":120},{"nctId":"NCT02541734","phase":"PHASE1, PHASE2","title":"Effect of Gelofusine on GLP1-receptor Imaging","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus","enrollment":12},{"nctId":"NCT02650479","phase":"PHASE1","title":"Study of the Effects of Intravenous Exenatide on Cardiac Repolarization","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2016-01","conditions":"Healthy Adult Male and Female Volunteers","enrollment":82},{"nctId":"NCT01140893","phase":"PHASE2, PHASE3","title":"Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2010-11","conditions":"Type 2 Diabetes","enrollment":110},{"nctId":"NCT01938235","phase":"PHASE2","title":"Exenatide for Myocardial Protection During Reperfusion Study","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2014-02","conditions":"Myocardial Infarction","enrollment":198},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT01281228","phase":"NA","title":"The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity","enrollment":48},{"nctId":"NCT00835848","phase":"PHASE4","title":"Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01","conditions":"Myocardial Infarction","enrollment":100},{"nctId":"NCT01021527","phase":"PHASE1","title":"A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Healthy","enrollment":12},{"nctId":"NCT00064714","phase":"PHASE2","title":"Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":"Diabetes Mellitus","enrollment":47},{"nctId":"NCT00736229","phase":"PHASE4","title":"Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2008-08","conditions":"Hyperglycemia, Acute Coronary Syndromes, Myocardial Infarction","enrollment":40},{"nctId":"NCT01181986","phase":"PHASE4","title":"The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes","status":"COMPLETED","sponsor":"Carl T. Hayden VA Medical Center","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT00747968","phase":"PHASE2, PHASE3","title":"The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2010-02","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT01254123","phase":"PHASE3","title":"Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-11","conditions":"Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","enrollment":40},{"nctId":"NCT00744224","phase":"NA","title":"PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-02","conditions":"Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Exenatide infusion","genericName":"Exenatide infusion","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce blood glucose in response to meals. Used for Type 2 diabetes mellitus (investigational infusion formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}